Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

The identification of anaplastic lymphoma kinase (ALK), an oncogenetic driver mutation, in lung cancer has paved the way for a new era in the treatment of non-small cell lung cancer (NSCLC). Targeting ALK using tyrosine kinase inhibitors (TKI) has dramatically improved the prognosis of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Akamine, Takaki, Toyokawa, Gouji, Tagawa, Tetsuzo, Seto, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110295/
https://www.ncbi.nlm.nih.gov/pubmed/30174447
http://dx.doi.org/10.2147/OTT.S165511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110295/
https://www.ncbi.nlm.nih.gov/pubmed/30174447
http://dx.doi.org/10.2147/OTT.S165511

Ejemplares similares